Department of Gastroenterology, Hyogo Cancer Center, Akashi, Hyogo, Japan.
PLoS One. 2021 Feb 26;16(2):e0247645. doi: 10.1371/journal.pone.0247645. eCollection 2021.
In Japan, South Korea, and Taiwan, nivolumab might provide overall survival benefits for patients with advanced gastric cancer. However, it is effective only in a limited number of patients. The Glasgow prognostic score is an indicator of the systematic inflammatory response and nutritional status. This study aimed to investigate the ability of the Glasgow prognostic score and other markers to predict the outcomes of patients treated with nivolumab. We reviewed the medical records of patients treated for advanced gastric cancer and who received nivolumab between February 2015 and June 2019 at Hyogo Cancer Center. The patients were categorized into two groups according to their Glasgow prognostic scores. Overall, 53.3% and 46.7% of the patients were assigned to groups with Glasgow prognostic scores of 0 and 1/2, respectively. The median durations of progression-free and overall survival of the participants were 2.3 and 5.7 months, respectively. The patients with a Glasgow prognostic score of 0 had significantly higher median overall survival than those with scores of 1 or 2 (16.4 vs. 4.2 months; p = 0.0006). This observation suggests that a pretreatment Glasgow prognostic score of 0 is associated with better outcomes, and this scoring system may be used as a predictor of outcomes in patients with advanced gastric cancer treated with nivolumab.
在日本、韩国和中国台湾地区，纳武利尤单抗可能为晚期胃癌患者带来总生存期获益。然而，它仅对有限数量的患者有效。格拉斯哥预后评分是系统性炎症反应和营养状况的指标。本研究旨在探讨格拉斯哥预后评分和其他标志物预测纳武利尤单抗治疗患者结局的能力。我们回顾了 2015 年 2 月至 2019 年 6 月在兵库癌症中心接受纳武利尤单抗治疗的晚期胃癌患者的病历。根据格拉斯哥预后评分，患者被分为两组。总体而言，分别有 53.3%和 46.7%的患者被分配到格拉斯哥预后评分为 0 和 1/2 的组。参与者的无进展生存期和总生存期的中位数分别为 2.3 个月和 5.7 个月。格拉斯哥预后评分为 0 的患者的中位总生存期明显长于评分为 1 或 2 的患者（16.4 与 4.2 个月；p=0.0006）。这一观察结果表明，治疗前格拉斯哥预后评分 0 与更好的结局相关，该评分系统可能可用于预测接受纳武利尤单抗治疗的晚期胃癌患者的结局。
